Kane Biotech Inc.
KNE.VTSXVHealthcare● Active
$0.03
+$0.01(+16.67%)
Market Cap$5455710
P/E Ratio—
52W High$0.07
52W Low$0.03
Kane Biotech Inc. (KNE.V) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KNE.V · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 28, 2026EPS Actual
-$0.00
Revenue
$0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 28, 2026
After Market Close
KNE.V reports quarterly as a TSXV-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q2 FY2026 | May 28, 2026 | — | -$0.00 | — | $0.00B | — | — |
| — Q4 FY2025 | Nov 28, 2025 | — | -$0.00 | — | $0.00B | — | — |
| — Q3 FY2025 | Aug 27, 2025 | — | -$0.00 | — | $0.00B | — | — |
| — Q2 FY2025 | Apr 28, 2025 | — | -$0.01 | — | $0.00B | — | — |
| — Q1 FY2025 | Mar 28, 2025 | — | $0.00 | — | $0.00B | — | — |
| — Q4 FY2024 | Nov 26, 2024 | — | -$0.00 | — | $0.00B | — | — |
| — Q3 FY2024 | Aug 29, 2024 | — | $0.06 | — | $0.00B | — | — |
| — Q2 FY2024 | May 23, 2024 | — | -$0.01 | — | $0.00B | — | — |
Q2 FY2026
May 28, 2026
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2025
Nov 28, 2025
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2025
Aug 27, 2025
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
Apr 28, 2025
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2025
Mar 28, 2025
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2024
Nov 26, 2024
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2024
Aug 29, 2024
EPS Actual
$0.06
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2024
May 23, 2024
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
No analyst estimates available for KNE.V.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 28, 2026 | — | $0.04 | $0.04 | +14.29% |
| — Q4 FY2025 | Nov 28, 2025 | — | $0.04 | $0.04 | -12.50% |
| — Q3 FY2025 | Aug 27, 2025 | — | $0.04 | $0.04 | +14.29% |
| — Q2 FY2025 | Apr 28, 2025 | — | $0.10 | $0.10 | +5.26% |
| — Q1 FY2025 | Mar 28, 2025 | — | $0.10 | $0.09 | -5.26% |
| — Q4 FY2024 | Nov 26, 2024 | — | $0.12 | $0.12 | +0.00% |
| — Q3 FY2024 | Aug 29, 2024 | — | $0.15 | $0.16 | +6.90% |
| — Q2 FY2024 | May 23, 2024 | — | $0.15 | $0.15 | +3.45% |
Q2 FY2026+14.29%
Report Date
May 28, 2026
EPS Beat/Miss
—
Price Before
$0.04
Price After
$0.04
Q4 FY2025-12.50%
Report Date
Nov 28, 2025
EPS Beat/Miss
—
Price Before
$0.04
Price After
$0.04
Q3 FY2025+14.29%
Report Date
Aug 27, 2025
EPS Beat/Miss
—
Price Before
$0.04
Price After
$0.04
Q2 FY2025+5.26%
Report Date
Apr 28, 2025
EPS Beat/Miss
—
Price Before
$0.10
Price After
$0.10
Q1 FY2025-5.26%
Report Date
Mar 28, 2025
EPS Beat/Miss
—
Price Before
$0.10
Price After
$0.09
Q4 FY2024+0.00%
Report Date
Nov 26, 2024
EPS Beat/Miss
—
Price Before
$0.12
Price After
$0.12
Q3 FY2024+6.90%
Report Date
Aug 29, 2024
EPS Beat/Miss
—
Price Before
$0.15
Price After
$0.16
Q2 FY2024+3.45%
Report Date
May 23, 2024
EPS Beat/Miss
—
Price Before
$0.15
Price After
$0.15
Beat Rate0 / 8 quarters
Largest Move+14.29% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KNE.V ends December
Kane Biotech Inc. (KNE.V) most recently reported earnings on May 28, 2026 for Q2 FY2026, posting EPS of $-0.00 (in line with the analyst consensus of —). The next KNE.V earnings date is expected around September 1, 2026.
Each quarter, investors track KNE.V earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KNE.V revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KNE.V's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KNE.V earnings · 4 questionsKane Biotech Inc.'s next earnings report is expected around September 1, 2026. KNE.V typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KNE.V historically reports after market close (AMC).
KNE.V earnings datewhen is KNE.V earningsKNE.V next earnings datewhen does KNE.V report earningsKNE.V earnings calendar
▸ Source: FMP · Kane Biotech Inc. SEC filings · US GAAP · Kane Biotech Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026